RxDoctor Payments Data

Nighat Saeed, MD

Family · Bronx, NYNPI 1780086355

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (44.3%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. AbbVie accounts for 86.3% of it on its own, with 27 other manufacturers making up the rest. Among family clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,717in general payments, 2019–2025

Across 200 payments — averaging $93.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$16K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$796
  • Sanofi$550
  • Ardelyx, Inc.$252
  • Nestle Healthcare Nutrition Inc.$111
  • Ironwood Pharmaceuticals, Inc$83
  • plus $777 from 22 others

What the payments were for

  • Speaking & faculty fees$8,30044%
  • Travel & lodging$6,47735%
  • Food & beverage$3,94121%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,717 in reported general payments places this provider in the 95th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$85,661
Medicare patients
360
Services billed
880

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase56$251,810
CreonLipase/Protease/Amylase58$200,816
LinzessLinaclotide76$71,129
XifaxanRifaximin22$54,862
Sucralfate99$19,632
Mesalamine15$9,558
Lubiprostone38$7,820
Famotidine383$5,541
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates87$4,714
Omeprazole290$3,989
Pantoprazole Sodium263$3,180
Lactulose46$2,248
Esomeprazole Magnesium19$2,129
Misoprostol24$1,757
Budesonide DrBudesonide13$1,338

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$16,148$271,945134 claims
Aimmune Therapeutics, Inc.Zenpep$39$251,81056 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$796$54,86222 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,883 family providers in New York.

Other family in Bronx

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →